Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 164

1.

Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.

Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I.

Lancet Oncol. 2013 Aug;14(9):901-8. doi: 10.1016/S1470-2045(13)70277-8.

PMID:
23867211
2.

Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study.

Martin-Broto J, Cleeland CS, Glare PA, Engellau J, Skubitz KM, Blum RH, Ganjoo KN, Staddon A, Dominkus M, Feng A, Qian Y, Braun A, Jacobs I, Chung K, Atchison C.

Acta Oncol. 2014 Sep;53(9):1173-9. doi: 10.3109/0284186X.2014.910313.

PMID:
24834795
3.

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study.

Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, Roudier M, Smith J, Ye Z, Sohn W, Dansey R, Jun S.

Lancet Oncol. 2010 Mar;11(3):275-80. doi: 10.1016/S1470-2045(10)70010-3.

PMID:
20149736
4.

Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone.

Rutkowski P, Ferrari S, Grimer RJ, Stalley PD, Dijkstra SP, Pienkowski A, Vaz G, Wunder JS, Seeger LL, Feng A, Roberts ZJ, Bach BA.

Ann Surg Oncol. 2015 Sep;22(9):2860-8. doi: 10.1245/s10434-015-4634-9.

5.

Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.

Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, Jun S, Jacobs I.

Clin Cancer Res. 2012 Aug 15;18(16):4415-24. doi: 10.1158/1078-0432.CCR-12-0578.

6.

Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.

Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, Asami Y, Inoue T, Yoneda T.

Ann Oncol. 2015 Oct;26(10):2149-54. doi: 10.1093/annonc/mdv307.

7.

Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): For how long?

Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP.

Eur J Cancer. 2017 Mar 16;76:118-124. doi: 10.1016/j.ejca.2017.01.028. [Epub ahead of print]

PMID:
28324746
8.

Denosumab: a new treatment option for giant cell tumor of bone.

Lewin J, Thomas D.

Drugs Today (Barc). 2013 Nov;49(11):693-700. doi: 10.1358/dot.2013.49.11.2064725. Review.

PMID:
24308016
9.

Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.

Demirsoy U, Karadogan M, Selek Ö, Anik Y, Aksu G, Müezzinoglu B, Corapcioglu F.

J Pediatr Hematol Oncol. 2014 Mar;36(2):156-8. doi: 10.1097/MPH.0000000000000034.

PMID:
24072245
10.

Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.

Federman N, Brien EW, Narasimhan V, Dry SM, Sodhi M, Chawla SP.

Paediatr Drugs. 2014 Feb;16(1):21-8. doi: 10.1007/s40272-013-0051-3.

PMID:
24114694
11.

Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.

Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman RE, Paterson AH, Gao GM, Kinsey AC, Peterson MC, Jun S.

Clin Cancer Res. 2008 Oct 15;14(20):6690-6. doi: 10.1158/1078-0432.CCR-07-5234.

12.

Denosumab for the treatment of giant cell tumor of the bone.

Brodowicz T, Hemetsberger M, Windhager R.

Future Oncol. 2015;11(13):1881-94. doi: 10.2217/fon.15.94.

PMID:
26161925
13.

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.

Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J.

Lancet Oncol. 2015 Jun;16(6):729-36. doi: 10.1016/S1470-2045(15)70198-1.

PMID:
25981813
14.

Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.

Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S.

J Clin Oncol. 2007 Oct 1;25(28):4431-7.

PMID:
17785705
15.

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial.

Machiels JP, Subramanian S, Ruzsa A, Repassy G, Lifirenko I, Flygare A, Sørensen P, Nielsen T, Lisby S, Clement PM.

Lancet Oncol. 2011 Apr;12(4):333-43. doi: 10.1016/S1470-2045(11)70034-1.

PMID:
21377930
16.

Denosumab treatment of giant cell tumour of bone.

Balke M.

Lancet Oncol. 2013 Aug;14(9):801-2. doi: 10.1016/S1470-2045(13)70291-2. No abstract available.

PMID:
23867210
17.

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S.

Lancet Oncol. 2014 Dec;15(13):1513-20. doi: 10.1016/S1470-2045(14)70489-9.

PMID:
25456370
18.

Clinicopathological Features of a Series of 27 Cases of Post-Denosumab Treated Giant Cell Tumors of Bones: A Single Institutional Experience at a Tertiary Cancer Referral Centre, India.

Rekhi B, Verma V, Gulia A, Jambhekar NA, Desai S, Juvekar SL, Bajpai J, Puri A.

Pathol Oncol Res. 2017 Jan;23(1):157-164. doi: 10.1007/s12253-016-0123-0. Epub 2016 Oct 8.

PMID:
27722984
19.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304.

PMID:
21343556
20.

Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases.

Yonemori K, Fujiwara Y, Minami H, Kitagawa K, Fujii H, Arai T, Sohn W, Ohkura M, Ohtsu T.

Cancer Sci. 2008 Jun;99(6):1237-42. doi: 10.1111/j.1349-7006.2008.00803.x.

Supplemental Content

Support Center